Opexa Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the closing of the previously announced underwritten public offering of 4,120,000 shares of its common stock, including the full exercise of the over-allotment option granted to the underwriters to purchase an additional 618,000 shares of its common stock, at a price to the public of $1.70 per share. The gross proceeds to Opexa from this offering were $8,054,600, before deducting underwriting discounts and commissions and other estimated offering expenses and including the full exercise of the over-allotment option. All of the shares in the offering were sold by Opexa.